Videos
Allergy Ranks Highest Impact Factor in Allergy
We are thrilled to announce that the 2024 journal Impact Factors stablished by Clarivate has been released, and we are immensely proud to share that Allergy has been recognised with a Impact Factor of 12.6 as the number one journal in our speciality of Allergy and Clinical Immunology. This outstanding achievement is a testament to the entire team's unwavering commitment and hard work.
The success of Allergy is rooted in several key factors:
Full Commitment and Hard Work: The dedication of our editorial and support teams has been instrumental in driving the journal to new heights.
Rapid Decisions for Submissions: Our efficient submission process ensures that authors receive timely and comprehensive feedback.
Extensive and High-Quality Reviews: We maintain rigorous peer review standards to ensure the publication of only the highest quality research.
Timely Publications: Speedy yet thorough processing of manuscripts guarantees that important research reaches the community promptly.
High Numbers of Impressions and Downloads: The significant engagement with our published papers highlights the journal’s influence and reach within the scientific community.
On behalf of the EAACI Executive Committee, it is our pleasure to extend our heartfelt gratitude to the entire Allergy team.
Special thanks to our Editor-in-Chief, Cezmi Akdis, for his visionary leadership, and our Deputy Editors, Ioana Agache and Marek Jutel, for their invaluable contributions. We also recognize the vital roles of our Associate Editors, including Heimo Breiteneder, Thomas Eiwegger, Wytske Fokkens, Emma Guttman-Yassky, David Jackson, Kari Nadeau, Robyn O’Hehir, Liam O’Mahony, Oliver Pfaar, Alexandra Santos, Claudia Traidl-Hoffmann, De Yun Wang, and Luo Zhang, along with the entire editorial board for their expertise and dedication.
In addition, our heartfelt thanks go to our Managing Editor, Laura Alberch; Graphics Editor, Anna Globinska; Social Media Editor, Ruya Kilic Ogulur; Associate Managing Editor, Marisa McGarry; Production Editor, Sathish Asokan Kannan, and Journal’s Publishing Manager, Lisbeth Cranfield.
Together, we have set a new standard of excellence in Allergy and Clinical Immunology, and we look forward to continuing this upward trajectory. Thank you to everyone who has contributed to making #Allergy a leader in our field!
Maria Torres
EAACI President
Articles
Reply to Correspondence: The Bronchodilator and Anti-Inflammatory Effect of Long-Acting Muscarinic Antagonists in Asthma: An EAACI Position Paper
Agache, I., Adcock, I.M., Akdis, C.A., et al. Allergy. First published: 11 April 2025
Correspondence to ‘Interleukin-5 as a Pleiotropic Cytokine Orchestrating Airway Type 2 Inflammation: Effects on and Beyond Eosinophils’
McCrae, C., Jison, M.L. and Menzies-Gow, A. Allergy. First published: 10 April 2025
Association Between Occupational Exposure and Sinus Surgery Outcomes in Chronic Rhinosinusitis: A Prospective Study
Vansteelant, G., Dietz de Loos, D.A.E., Ronsmans, S.,et al. Allergy. First published: 10 April 2025
Faecalibacterium in the Gut Microbiota Predicts Tolerance Acquisition in Pediatric Hen's Egg Allergy
Akagawa, S., Tsuji, S., Nakai, Y., et al. Allergy. First published: 10 April 2025
Vaccine-Induced Anti-IgE Antibodies Neutralize Free IgE but Fail to Bind and Activate Mast Cell-Displayed IgE
Gharailoo, Z., Vogel, M., Engeroff, P. and Bachmann, M.F. Allergy. First published: 07 April 2025
Management of Patients With Allergic Diseases in the Era of Biologics
Lan, F., Akdis, C.A. and Zhang, L. Allergy. First published: 05 April 2025
Recombinant Hypoallergenic Cat Allergy Vaccines
Trifonova, D., Curin, M., Focke-Tejkl, M., et al. Allergy. First published: 03 April 2025
Flow Cytometry-Assisted Analyses of Individual Human Basophils, Mast Cells and T Cells in the Diagnosis of Immediate Drug Hypersensitivity: A Review
Elst, J., Mertens, C., Van Houdt, M., van der Poorten, et al. Allergy. First published: 03 April 2025
TOP10-SCAR: A Global Pharmacovigilance Study on Medications Most Frequently Related to Severe Cutaneous Adverse Reactions
Cho, J., Jo, H., Park, J.,et al. Allergy. First published: April 2025
NLRC4 Regulates Th2 Differentiation in Mice With Allergic Airway Inflammation Induced by House Dust Mite
Pak, S.-W., Kim, W.-I., Lee, S.-J., et al. Allergy. First published: 02 April 2025
Meta-Analysis of PQ Grass 27600 SU Efficacy and Quality of Life From Phase III Trials
Zielen, S., Bernstein, J.A., Pfaar, O., et al. Allergy. First published: 31 March 2025
Immunological In Vitro Assay for Quantification of Adjuvanted Allergoids
Schlünder, S., Echternach, J., Bartel, D., et al. Allergy. First published: 31 March 2025
Anatomical Distribution and Quantification of IgE Secretion in Mouse Models of House Dust Mite Allergy
Haase, P., Perima, A., Ramnarayan, V.R., et al. Allergy. First published: 31 March 2025
The Epidemiology of Chronic Urticaria in Cape Town, South Africa: A Review of Two Tertiary Referral Centers
Day, C., Deetlefs, M., Mapahla, L., et al. Allergy. First published: 31 March 2025
Access to Epinephrine Autoinjectors, the Patient Perspective
Baichoo, N., Fishbein, J. and Ponda, P. Allergy. First published: 29 March 2025
Head-To-Head Comparison of Biologic Efficacy in Asthma: What Have We Learned?
Lipworth, B.J., Greig, R., Chan, R., et al. Allergy. First published: 29 March 2025
Clinical, Epidemiological, Virological Characteristics and Outcomes of 286 Patients Infected With Monkeypox Virus in China
Hu, H., Zheng, Y., Ruan, L., et al. Allergy. First published: 27 March 2025
Cytokine Variations After Positive Oral Food Challenges in Adult-Onset Food Protein-Induced Enterocolitis
Gonzalez-Delgado, P., Anvari, S., Jimenez, A.I., et al. Allergy. First published: 27 March 2025
Safety and Tolerability of a 3-h Build-Up Phase With Hymenoptera Venom Depot Extracts: Preliminary Results
Buonomo, A., Massaro, R., Longhino, D., et al. Allergy. First published: 24 March 2025
Dopamine as a Potential Modulator of ILC2-Driven Lung Inflammation via Mitochondrial Regulation
Silva, G., Alves, P.B. and Regateiro, F. Allergy. First published: 24 March 2025
Allergic Signature in Delayed Cross-Hypersensitivity to all Iodinated Contrast Media
Do, D., Bertolotti, L., Mosnier, A., et al. Allergy. First published: 22 March 2025
Correspondence: Causal Associations Between Chronic Spontaneous Urticaria and Thyroid Function Indicators in Different Ethnic Groups: A Bidirectional Two-Sample Mendelian Randomization Analysis
Zhang, Y., Zhou, J. and Ni, Y. Allergy. First published: 21 March 2025
Atopic Status Is Associated With Kidney Transplanted Recipients' Outcomes
Colas, L., Lorent, M., Feuillet, F., et al. Allergy. First published: 20 March 2025
Wildfires and Respiratory Allergy
D'Amato, G., Agache, I., Nadeau, K., et al. Allergy. First published: 19 March 2025
A Safe and Efficient 7-Week Immunotherapy Protocol With Aluminum Hydroxide Adsorbed Bee Venom
Arzt-Gradwohl, L., Čerpes, U., Schadelbauer, E., et al. Allergy. First published: 15 March 2025
The Omics Landscape of Long COVID—A Comprehensive Systematic Review to Advance Biomarker, Target and Drug Discovery
Baalbaki, N., Slob, E.M.A., Kazer, S.W., et al Allergy. First published: 14 March 2025
3D Model of Human Epidermis Exposed to Staphylococci Reveals Keratinocyte Responses Unique to Atopy-Associated S. aureus Challenge
Brzoza, P., Camacho, M., Tyshchenko, M., et al. Allergy. First published: 13 March 2025
Torres, M.J., Bonadonna, P. and Guéant, J.-L.Legends of Allergy and Immunology: Antonino Romano
Torres, M.J., Bonadonna, P. and Guéant, J.-L. Allergy. First published: 12 March 2025
Immunophenotyping in Vernal Keratoconjunctivitis: Schirmer Test for Therapy Response Prediction
Bilotta, M.T., Vacca, P., Esposito, M., et al. Allergy. First published: 12 March 2025
Correspondence to “The Bronchodilator and Anti-Inflammatory Effect of Long-Acting Muscarinic Antagonists in Asthma: An EAACI Position Paper”
Semenzato, U., Previtero, D., Padrin, Y., et al. Allergy. First published: 11 March 2025
Comparative Evaluation of an Allergen Exposure Chamber and Nasal Allergen Challenge Versus In-Field Symptom Assessment in Patients With Allergic Rhinitis Triggered by Timothy Grass Pollen
Zemelka-Wiacek, M., Kosowska, A., Pfaar, O., et al. Allergy. First published: 09 March 2025
Asthma Control and Risk Factors for Poor Asthma Outcomes in Chinese Asthma Patients: Baseline Analysis of a Multi-Centre, Single-Arm Study (CARE4ALL)
Huang, K., Liu, M., Wang, W., et al. Allergy. First published: 09 March 2025
A Single Multiplex CytoBas Assay Incorporating Eight Major Components for Accurate Detection of Allergen Sensitization in Asthma and Allergic Rhinitis
Hsin, L., Hew, M., Aui, P.M., et al. Allergy. First published: 07 March 2025
Efficacy and Safety Profile of Animal Dander Immunotherapy: A Multicentre UK Study
Kim, D.-I.S., Kasternow, B., Grammatikos, A., et al.Allergy. First published: 07 March 2025
The Role of IgE in Crohn's Disease by Impairing the Capacity of Plasmacytoid Dendritic Cells to Generate FOXP3+ Tregs
de la Rocha-Muñoz, A., Benito-Villalvilla, C., Olivares, D., et al. Allergy. First published: 07 March 2025
Non-Allergic Urticarial Skin Reactions Associated With MOv18 IgE, a First-In-Class IgE Antibody Recognising Folate Receptor Alpha
Stavraka, C., Chauhan, J., Crescioli, S., et a. Allergy. First published: 06 March 2025
Reply to Correspondence: What Is the Next Step for Patients With Aspirin-Exacerbated Respiratory Disease: Biologics With or Without Aspirin Therapy?
Doña, I., de Santa María, R.S., Moreno, E.M., et al. Allergy. First published: 06 March 2025
Targeting the Galectin-7/TRPM2/Zn2+/DRP-1 Signaling Pathway: A Potential Therapeutic Intervention in the Pathogenesis of SJS/TEN
Zhang, C., Pang, B., Luo, Y., et al. Allergy. First published: 05 March 2025
Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps
Xian, M., Yan, B., Song, X., et al. Allergy. First published: 05 March 2025
Particulate Matter 2.5 Aggravates Airway Inflammation by Neutrophil-Mediated Inflammasome Activation
Chen, T.-H., Chou, C.C.K. and Chiang, B.-L.Allergy. First published: 05 March 2025
Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate-to-Severe Atopic Dermatitis
Paller, A.S., Eichenfield, L.F., Irvine, A.D., et al. Allergy. First published: 03 March 2025
Phase 2-3 Trial: Prevention of the Progression to Moderate and Severe COVID-19 in SARS-CoV-2-Infected Non-Hospitalized Adults With Inhaled siRNA-Based MIR 19
Khaitov, M., Nikonova, A., Smirnov, V., et al. Allergy. First published: 03 March 2025
EAACI Guidelines on Environmental Science for Allergy and Asthma—Recommendations on the Impact of Indoor Air Pollutants on the Risk of New-Onset Asthma and on Asthma-Related Outcomes
Agache, I., Annesi-Maesano, I., Cecchi, L., et al. Allergy. First published: 28 February 2025
Citations: 342
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, Aquilina, S, Asero, R, Baker, D, et al. Allergy. 2022; 77: 734– 766
Citations: 147
EAACI guidelines: Anaphylaxis (2021 update)
Muraro A, Worm M, Alviani C, et al. Allergy. 2022; 77: 357–377
Citations: 118
The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update
Maurer M, Magerl M, Betschel S, et al. Allergy. 2022; 77: 1961–1990
Citations: 118
The role of peripheral blood eosinophil counts in COVID-19 patients
Xie, G, Ding, F, Han, L, Yin, D, Lu, H, Zhang, M. Allergy. 2021; 76: 471– 482
Citations: 114
Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease
Celebi Sozener Z, Ozdel Ozturk B, Cerci P, et al. Allergy. 2022; 77: 1418–1449
Citations: 105
Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice
Santos, A.F., Alpan, O. and Hoffmann, H.-J. Allergy. 2021; 76: 2420-2432
Citations: 92
Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation
Klimek, L., Novak, N., Cabanillas, B., et al. Allergy. 2021; 76: 3307-3313
Citations: 90
EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines
Sokolowska, M., Eiwegger, T., Ollert, M., Torres, M.J., Barber, D., Del Giacco, S., et al. Allergy. 2021; 76: 1629-1639
Citations: 88/h5>
The role of allergen-specific IgE, IgG and IgA in allergic disease
Shamji MH, Valenta R, Jardetzky T, et al. Allergy. 2021; 76: 3627–3641
Citations: 82
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper
Pfaar, O, Klimek, L, Jutel, M, Akdis, C, A, Bousquet, J, Breiteneder, H, et al. Allergy. 2021; 76: 648– 676
Citations: 81
Advances and highlights in allergic rhinitis
Zhang Y, Lan F, Zhang L. Allergy. 2021; 76: 3383–3389
Citations: 79
Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?
Cabanillas, B., Akdis, C.A. and Novak, N. Allergy. 2021; 76: 1617-1618
Citations: 76
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines
Agache, I., Song, Y., Alonso-Coello, P., Vogel, Y., Rocha, C., Solà, I., et al. Allergy. 2021; 76: 2337-2353
Citations: 74
Interleukin-31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997
Citations: 73
Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches
Kato A, Peters AT, Stevens WW, Schleimer RP, Tan BK, Kern RC. Allergy. 2022; 77: 812–826
Citations: 70
Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives
Sampath, V., Rabinowitz, G., Shah, M., et al. Allergy. 2021; 76: 1640-1660
Citations: 69
Advances and highlights in biomarkers of allergic diseases
Ogulur I, Pat Y, Ardicli O, et al. Allergy. 2021; 76: 3659–3686
Citations: 69
Regulatory B cells, A to Z
Jansen, K., Cevhertas, L., Ma, S., Satitsuksanoa, P., Akdis, M. and van de Veen, W.
Citations: 62
Advances and highlights in asthma in 2021
Agache I, Eguiluz-Gracia I, Cojanu C, et al. Allergy. 2021; 76: 3390–3407
Citations: 62
Predictors of treatment response in chronic spontaneous urticaria
Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981
Citations: 61
The ingenious mast cell: Contemporary insights into mast cell behavior and function
Dahlin, J.S., Maurer, M., Metcalfe, D.D., Pejler, G., Sagi-Eisenberg, R. and Nilsson, G. Allergy. 2022; 2022; 77: 83-99
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, et al. Allergy. 2022; 77: 734– 766
The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A., H., Baker, D., Ballmer-Weber, B. et al. Allergy. 2018; 73: 1393- 1414
Risk factors for severe and critically ill COVID-19 patients: A review
Gao, Y-D, Ding, M, Dong, X, et al. Allergy. 2021; 76: 428– 455
Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives
Sampath, V., Rabinowitz, G., Shah, M., Jain, S., Diamant, Z., Jesenak, M. et al. Allergy. 2021; 76: 1640-1660
Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19
Azkur, A.,K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M.,C. et al. Allergy. 2020; 75: 1564– 1581
EAACI guidelines: Anaphylaxis (2021 update)
Muraro, A, Worm, M, Alviani, C, et al. Allergy. 2022; 77: 357– 377
Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
Bousquet, J., Khaltaev, N., Cruz, A.A., Denburg, J., Fokkens, W.J., Togias, A. et al. Allergy. 2008; 63: 8-160
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China
Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yan, Y.-Q., Akdis, C., A. and Gao, Y.-D. Allergy. 2020; 75: 1730– 1741
Advances and recent developments in asthma in 2020
Cevhertas, L, Ogulur, I, Maurer, DJ, et al. Allergy. 2020; 75: 3124– 3146
The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update
Maurer, M., Magerl, M., Betschel, S., et al. Allergy. First published: 10 January 2022
A compendium answering 150 questions on COVID-19 and SARS-CoV-2
Riggioni, C., Comberiati, P., Giovannini, M., Agache, I., Akdis, M., Alves-Correia, M. et al. Allergy. 2020; 75: 2503– 2541
Special Issue: Perspectives in Allergen Immunotherapy: 2019 and Beyond
Volume 74 | Issue S108
Management of anaphylaxis due to COVID-19 vaccines in the elderly
Bousquet, J., Agache, I., Blain, H., et al. Allergy. 2021; 76: 2952-2964
Predictors of treatment response in chronic spontaneous urticaria
Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981
Interleukin-31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997
Markers for the involvement of endothelial cells and the coagulation system in chronic urticaria: A systematic review
Mostmans, Y., De Smedt, K., Richert, B., et al. Allergy. 2021; 76: 2998-3016
Eczema herpeticum in atopic dermatitis
Traidl, S., Roesner, L., Zeitvogel, J. and Werfel, T. Allergy. 2021; 76: 3017-3027
CytoBas: Precision component-resolved diagnostics for allergy using flow cytometric staining of basophils with recombinant allergen tetramers
McKenzie, C.I., Varese, N., Aui, P.M., et al. Allergy. 2021; 76: 3028-3040
Heterogeneity of pollen food allergy syndrome in seven Southern European countries: The @IT.2020 multicenter study
Lipp, T, Acar Şahin, A, Aggelidis, X, et al. Allergy. 2021; 76: 3041– 3052
Direct assessment of individual skin barrier components by electrical impedance spectroscopy
Mannweiler, R., Bergmann, S., Vidal-y-Sy, S., Brandner, J.M. and Günzel, D. Allergy. 2021; 76: 3094-3106
Prenatal paraben exposure and atopic dermatitis-related outcomes among children
Thürmann, L, Herberth, G, Seiwert, B, et al. Allergy. 2021; 76: 3122– 3132
Free human DNA attenuates the activity of antimicrobial peptides in atopic dermatitis
Kopfnagel, V, Dreyer, S, Zeitvogel, J, et al. Allergy. 2021; 76: 3145– 3154
Nanoarchitectures for efficient IgE cross-linking on effector cells to study amoxicillin allergy
Tesfaye, A., Rodríguez-Nogales, A., Benedé, S., et al. Allergy. 2021; 76: 3183-3193
Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine
Darrigade, A.-S., Théophile, H., Sanchez-Pena, P., et al. Allergy. 2021; 76: 3194-3196
Transgenic mice overexpressing the PGE2 receptor EP2 on mast cells exhibit a protective phenotype in a model of allergic asthma
Urbano, A., Plaza, J., Turon, S., et al. Allergy. 2021; 76: 3196-3199
Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma
Lommatzsch, M., Klein, M., Stoll, P. and Virchow, J.C. Allergy. 2021; 76: 3199-3202
Identification of Ulocladium chartarum as an important indoor allergen source
Pfeiffer, S., Sandler, P., Raith, M., et al. Allergy. 2021; 76: 3202-3206
Effects of allergen immunotherapy in the MASK-air study: a proof-of-concept analysis
Pfaar, O., Sousa-Pinto, B., Devillier, P., et al. Allergy. 2021; 76: 3212-3214
Predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance
Remington, B.C., Koppelman, S.J., Green, T.D., et al. Allergy. 2021; 76: 3223-3226
Legends of allergy and immunology: Sergio Bonini
Maltese, G. and Rasi, G. Allergy. 2021; 76: 3227-3229
Medical algorithm: Peri-operative management of mastocytosis patients
Bocca-Tjeertes, I.F.A., van de Ven, A.A.J.M., Koppelman, G.H., et al. Allergy. 2021; 76: 3233-3235
Open Access Agreements with Wiley
Check here if your research institution has an agreement with Wiley to make your Original Articles and Review Articles free to read, download and share by everyone: Institutional Payments | Wiley
Junior Members Corner
Dear Juniors,
From November 21-23, EAACI Junior Member Assembly (JMA) representatives participated in the latest edition of the Food Allergy and Anaphylaxis Meeting and the European Consortium on the Application of Flow Cytometry in Allergy (FAAM-EUROBAT 2024) in the beautiful city of Athens, Greece. During this EAACI Focus Meeting, we had the opportunity to explore the latest advancements in food allergy and anaphylaxis with leading experts in the field. The involvement of Juniors, especially in the oral and poster sessions, was fantastic, as well as their participation in social and networking activities. A highlight was the celebration of Anaphylaxis Awareness Day on the first day of the meeting. EUROBAT brings together world-renowned experts focused on flow cytometry for the study of allergic reactions, with particular emphasis on the Basophil Activation Test (BAT) and the Mast Cell Activation Test (MAT).
Right after the focus meeting, the JMA held its first business meeting following its establishment at the EAACI 2024 Congress in Valencia, Spain. Over two exciting days, JMA members gathered to discuss the organization and planning of activities, as well as new initiatives and projects. We also had the chance to engage with EAACI leadership, including Maria Jose Torres and Mohamed Shamji, EAACI President and General Secretary. We were also privileged to attend scientific talks from experts like Nikos Papadopoulos and Sophia Tsabouri, along with insights from Ozlem Ceylan, chair of the patient organization. We look forward to expanding current JMA activities and hope you will find the new initiatives interesting. Stay tuned to EAACI JMA's social media and outreach channels so you don’t miss any updates!
Best regards,
The Junior Member Assembly
EAACI Patients Organisation Committee Corner
The POC Reunion in the Annual Congress 2023
The POC has been participating in the EAACI Annual Congresses and focused meetings such as FAAM and PAAM since 2011. When Covid-19 pandemic and strict public health measures started in 2020, POC members continued attending the EAACI events virtually. For the first time in a long while, the POC returned to in-person participation in the Annual Congress Hamburg 2023.
Fifteen members of the committee attended the Annual Congress 2023 in-person. The special session ESS1 which was completely organised by the POC took place on the first day of the Congress with great success. Session was designed to discuss the “Benefits of engaging with patients in clinical trials and decision-making” with different stakeholders.
Giulia Gabrielli from European Medicine Agency (EMA) shared the framework for engagement between the Agency and the patients. Dr Kirsten Perrett, Director of Australia National Allergy Centre of Excellence, shared their experience in receiving the federal funding for allergy prevention and management in collaboration with the POC member Allergy & Anaphylaxis Australia. Susanna Palkonen, Director of European Federation of Allergy and Airways Diseases Patients Associations (EFA) presented their long-lasting track record in participation to research projects. POC Member Mikaela Odemyr, President of Asthma and Allergy Association Sweden shared her experience as a patient representative in participating the research design and planning process.
The session chairs were Carla Jones, CEO of Allergy UK, past POC Co-Chair and Ozlem Ceylan, President of Living with Allergy Association, current POC Chair. The session also had a panel discussion where chairs invited the audience to share their experiences and best practises.
Additionally, POC members Sabine Schnadt (DAAB-Germany) presented “Managing the risk of patients with peanut allergy: the value of thresholds of reaction” in the industry session, Patricia Carmelo and Carolina Olivares (Fundacion Creciendo con Alergias Alimenarias-Chile) had two poster presentations; “Food Allergens that trigger anaphylaxis in children in Chile” and “Adrenaline Auto-injector in Chile, National Survey 2020”.
Several POC members attended the Beat Allergy Run & Walk on the 10th of June. The event was organised to contribute on providing much-needed aid as the collected funds were sent to those affected by the earthquakes in Turkey.
The POC believes the conferences and in-person meetings are useful in staying up to date with new developments in medicine, dissemination of knowledge, enabling interaction with opinion leaders, networking, developing consensus, and adoption of newer ideas relevant to the patient community. Going forward, committee members consider hybrid conventions a decent opportunity to increase accessibility and inclusivity. In 2024, POC is planning to attend the Annual Congress in Valencia and FAAM in Athens.
